In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1)

Rutter, M K; Prais, H R; Charlton-Menys, V; Gittins, M; Roberts, C; Davies, R R; Moorhouse, A; Jinadev, P; France, M; Wiles, P G; Gibson, J M; Dean, J; Kalra, P A; Cruickshank, J K; Durrington, P N

Diabet Med. 2011;28(1):100-8.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally

Abstract

AIMS: To compare the renal effects of low- vs. high-dose atorvastatin in patients with Type 2 diabetes mellitus and optimally managed early renal disease. METHODS: We compared the 2-year progression of nephropathy in a double-blind randomized controlled trial of atorvastatin 80 mg/day (n = 60) vs. 10 mg/day (n = 59) in patients with Type 2 diabetes with microalbuminuria or proteinuria [mean (sd): age 64 years (10 years); HbA(1c) 7.7% (1.3%), 61 mmol/mol (10 mmol/mol); blood pressure 131/73 mmHg; renin-angiotensin system blocker use > 80%; dual blockade > 67%] recruited from diabetes clinics in Greater Manchester. RESULTS: Over (mean) 2.1 years of follow-up, the Modification of Diet in Renal Disease estimated glomerular filtration rate declined by 3 ml min(-1) 1.73 m(-2) in the combined group. The mean (95% CI) between-group difference during follow-up was not significant [2.2 ml min(-1) 1.73 m(-2) (-1.1 to 5.4 ml min(-1) 1.73: m(-2) ), P = 0.20] after adjusting for baseline differences in renal function; positive difference favours 80 mg dose. Similarly, there was no significant difference in creatinine clearance by Cockcroft and Gault [2.5 ml/min (-2.4 to 7.3 ml/min), P = 0.32]; serum creatinine/24-h urine collections [4.0 ml/min (-4.8 to 12.7 ml/min), P = 0.38]; cystatin C (P = 0.69); or 24-h urine protein or albumin excretion (P = 0.92; P = 0.93). We recorded no significant between-group differences in deaths or adverse events. CONCLUSIONS: In patients with Type 2 diabetes with early renal disease, we found no statistical difference in renal function between those taking high- or low-dose atorvastatin over 2 years. We cannot exclude a beneficial effect of < 1.6 ml min(-1) 1.73 m(-2) year(-1) on Modification of Diet in Renal Disease estimated glomerular filtration rate, or if blood pressure management or if renin-angiotensin system blocker use had not been optimized.

Bibliographic metadata

Type of resource:
Content type:
Published date:
Language:
eng
Journal title:
Volume:
28
Issue:
1
Start page:
100
End page:
8
Total:
-91
Pagination:
100-8
Digital Object Identifier:
10.1111/j.1464-5491.2010.03139.x
ISI Accession Number:
21166851
Related website(s):
  • Related website http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21166851
General notes:
  • Rutter, M K Prais, H R Charlton-Menys, V Gittins, M Roberts, C Davies, R R Moorhouse, A Jinadev, P France, M Wiles, P G Gibson, J M Dean, J Kalra, P A Cruickshank, J K Durrington, P N Research Support, Non-U.S. Gov't England Diabetic medicine : a journal of the British Diabetic Association Diabet Med. 2011 Jan;28(1):100-8. doi: 10.1111/j.1464-5491.2010.03139.x.
Access state:
Active

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:151189
Created by:
Gibson, Martin
Created:
15th January, 2012, 14:43:55
Last modified by:
Gibson, Martin
Last modified:
27th October, 2015, 01:42:53

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.